Genesis MedTech has sold its JC Medical company to Edwards Lifesciences. This includes the intellectual property (IP) and commercial rights for the J-Valve transcatheter aortic valve replacement (TAVR) to treat severe aortic regurgitation.
 
Genesis still has the exclusive right to develop, manufacture, and commercialize the J-Valve system in China. In July 2023, the company finished patient enrollment for the J-Valve transfemoral system’s (J-Valve TF) clinical study to treat aortic regurgitation. The one-year patient follow-up was also recently completed.
 
In August 2023, J-Valve TF was awarded breakthrough status by the U.S. Food and Drug Administration (FDA). Enrollment for its U.S. early feasibility study was finished in February 2024 and JC Medical earned FDA approval to begin J-Valve TF’s pivotal clinical trial in the first half of this year.
 
Edwards also made a $25 million equity investment in Genesis MedTech. The funds will support its product and market development efforts, according to the company.
 
“J-VALVE has unique advantages in treating aortic valve regurgitation.” said Warren Wang, chairman and CEO of Genesis MedTech Group. “We hope that J-Valve can expand its global impact, enabling more patients to benefit from this innovative product. We will continue strengthening our focus on developing innovative products and explore better medical solutions to benefit more patients worldwide.”
 
Last month, Edwards announced two investments: one agreement to acquire JenaValve, and another to exercise the option to acquire Endotronix.